25/04/2026
New DM Management Landscape (NICE 2026 Update)
BIGGEST CHANGE: First-Line Therapy
New Standard:
Modified-release Metformin (MRM) + SGLT2 inhibitor for most patients
If Metformin not tolerated:
SGLT2 inhibitor alone
This is a major change: SGLT2 inhibitors moved from 2nd line → 1st line
COMORBIDITY-BASED PATHWAYS (Core of New NICE)
❤️ A. Heart Failure
Metformin + SGLT2 inhibitor
Avoid unnecessary escalation
❤️🔥 B. ASCVD (Atherosclerotic CVD)
Triple early therapy:
Metformin
SGLT2 inhibitor
GLP-1 RA (e.g., semaglutide)
Early aggressive therapy = ↓ CV events
-C. CKD (Chronic Kidney Disease)
eGFR >30 → Metformin + SGLT2
eGFR 20–30 → SGLT2 (dapagliflozin/empagliflozin) + DPP-4
eGFR